The GLP is committed to full transparency. Download and review our Annual Report.

Bayer sells animal health division for $7.6 billion, denies deal prompted by glyphosate-cancer lawsuits

| | August 21, 2019

Agriculture and pharmaceutical giant Bayer [August 20] agreed [to] a $7.6 billion deal to sell its animal health business to U.S.-based animal health company Elanco …. The deal with Elanco means Bayer will now no longer make products that prevent and treat diseases in farm animals and pets.

Bayer finds itself in a tough political situation after its $63 billion acquisition of glyphosate-maker Monsanto last year. Having taken on the liability for the controversial weedkiller, Bayer has been facing a wave of claims from plaintiffs saying glyphosate caused their cancer …. Bayer …. denied any link between the glyphosate lawsuits and the animal health sell-off.

Related article:  Natural Resources Defense Council sues EPA to block rollout of Dow Enlist Duo GMO system

Read full, original article: Bayer sells animal health business (Behind paywall)

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend